If you want to do a blood test in Valencia or in any other city in Spain, with a private insurance policy or as a private patient, then this page is for you. To do this, you need to send a request for a telephone consultation, indicating the necessary parameters to the doctor. After that, the doctor will contact you and you will be given a referral for tests.
In the Valencian Community (Comunidad Valenciana) and throughout Spain, laboratories (biochemical and genetic), where all laboratory examinations are available for all categories of patients. Many tests are specific to a particular disease or group of related diseases. You can also perform any blood test in your city if you have a referral.
If you are a resident of Spain, you can book a consultation with your private insurance policy (Sanitas, Adeslas, Asisa, Aegon, DKV). All costs for standard tests are covered by your insurance company.
This service includes only referral for tests. If you are a private patient, then having a referral, you go to any laboratory, and there you will be told the price of blood tests. We provide prices for tests only for those patients who are served in our clinics. Also not included in this service is the decoding of the results.
I would like to remind all patients and some specialists that the most important thing is complete and capacious medical history person, with all the details, and then laboratory research. Therefore, it is completely unacceptable to first do all sorts of tests, and then proceed to compiling the patient's medical history. All information is provided here for the correct orientation and familiarization of patients with all the existing possibilities of modern medicine in Spain, but, without a doubt, we strongly recommend that you do not engage in self-diagnosis.
The most frequently analyzed liquids are:
- Blood (STD test; CBC and urinalysis; DNA test; Semen test; HIV and Hepatitis test; Parasite test; Hormone test; Blood sugar test; HCG test; PSA test; PCR test ; analysis for any type of allergy; analysis of intolerance to anesthetics)
- Urine and culture for urinary infections
- The fluid that surrounds the spinal cord and brain (cerebrospinal fluid)
- Intra-articular fluid (synovial fluid)
- Less frequently, sweat, saliva, and fluid from the digestive tract (eg, gastric juice) are analyzed. In some cases, the analyzed fluids are present only in conjunction with a certain disease, for example, when fluid accumulates in the abdominal cavity (in the case of ascites), or which line the walls of the lungs (pleura)
- Screening - a type of test to detect an early stage or latent form of the disease
- Diagnosis of diseases and confirmation of the diagnosis - tumor markers
This table also includes two systems for measuring laboratory parameters: SI and Arbitrary units
Are you interested in specific blood test parameters?
| Parameter (Spanish) | Parameter (Russian) | Component of blood | Standard unit measurements | International SI |
|---|---|---|---|---|
| Acetoacetato | Acetoacetate | blood plasma | < 1 mg/dL | < 0.1mmol/L |
| Acetilcolinesterasa (ACE), RBC | Acetylcolinesterase | Blood | 26.7 a 49.2 U/g Hb | — |
| Phosfatasa acida | Acid phosphatase | Serum | 0.5-5.5U/L | 0-0.9µkat/L |
| Tiempo parcial de thromboplastina activada (aPTT) | Activated partial thromboplastin time (APTT) | Plasma | 25-35 seg | — |
| Hormona adrenocorticotropica (ACTH) | adrenocorticotropic hormone | Serum | 9-52 pg/mL | 2-11 pmol/L |
| Albumina | Albumen | Serum | 3.5 a 5.5 g/dl | 35-55g/L |
| Aldosterone: | Aldosterone: | |||
| De pie | Standing | Serum | 7-20ng/dL | 194-554 pmol/L |
| en decubito | Lying down | Serum | 2-5 ng/dL | 55-138 pmol/L |
| Fosfatasa alcalina (ALP) | Alkaline phosphatase | Serum | 36-92 U/L | 0.5-1.5µkat/L |
| Alfa1-antitripsina (AAT) | Alpha 1 antitrypsin | Serum | 83 a 199 mg/dL | — |
| Alfa fetoproteina (AFP) | Alphafetoprotein | Serum | 0-20ng/dL | 0-20pg/L |
| Ácido δ-aminolevulinico (ALA) | delta-aminolevulinic acid | Serum | 15-23 µg/L | 1.14-1.75 µmol/L |
| Aminotransferasa, alanina (ALT) | Alanine aminotransferase | Serum | 0-35U/L | 0-0.58 pkat/L |
| Aminotransferasa, aspartato (AST) | Aspartate aminotransferase | Serum | 0-35U/L | 0-0.58 pkat/L |
| Amoniaco | Ammonia | Plasma | 40-80µg/dL | 23-47 µmol/L |
| Amilasa | Amylase | Serum | 0-130U/L | 0-2.17µkat/L |
| Anticuerpos contra el antigeno nuclear extraíble (AENA) | Antibodies to nuclear antigens | Serum | <20,0 unidades | — |
| Anticuerpos anti-péptido citrulinado cíclico (anti-CCP) | Antibodies to petic citrated peptide (ACCP) | Serum | ≤ 5 uniforms | — |
| Hormona antidiuretica (ADH; arginina vasopresina) | Antidiuretic hormone | Plasma | <1,7 pg/mL | <1,57 pmol/L |
| Anticuerpos anti-DNA de doble cadena, IgG | Antibodies to double-stranded DNA | Serum | <25 UI | — |
| Anticuerpos antimitocondriales M2 | Antimitochondrial antibodies M2 | Serum | <0,1 unidades | — |
| Anticuerpos citoplasmaticos antineutrofilos (cANCA) | Antineutrophil Cytoplasmic Antibodies | Serum | Negative | — |
| Anticuerpos antinucleares (ANA) | Antimitochondrial bodies | Serum | ≤ 1 unidad | — |
| Título de anticuerpos antimúsculo liso (ASMA) | Antibodies to smooth muscle | Serum | ≤ 1:80 | — |
| Titulo de antiestreptolisina O | Antisteptolysin-O quantity | Serum | < 150 uniforms | — |
| Título de anticuerpos microsómicos antitiroideos | Microsomal thyroid antibodies | Serum | < 1:100 | — |
| α1-Antitripsina (AAT) | alpha-1-antitrypsin | Serum | 83-199 mg/dL | 15.3-36.6 µmol/L |
| Apolipoproteinas: | Apolipoproteins: | |||
| AI, women | AI, women | Serum | 98 - 210 mg/dL | 0.98 - 2.1 g/L |
| AI, men | AI, men | Serum | 88 . 180 mg/dL | 0.88 a 1.8 g/L |
| B-100, women | B-100, women | Serum | 44 - 148 mg/dL | 0.44 a 1.48 g/L |
| B-100, men | B-100, men | Serum | 55–151 mg/dL | 0.55 a 1.51 g/L |
| Bicarbonato | Bicarbonate | Serum | 23-28mEq/L | 23-28 mmol/L |
| Bilirubina: | Bilirubin: | |||
| directa | Straight | Serum | 0-0.3 mg/dL | 0–5.1 µmol/L |
| Total | General | Serum | 0.3–1.2 mg/dL | 5.1-20.5 µmol/L |
| volumen de sangre: | Blood parameters: | |||
| Plasma, mujeres | Plasma, women | Blood | 28-43 ml/kg de peso corporal | 0.028 - 0.043 L/kg de peso corporal |
| Plasma, varones | Plasma, men | Blood | 25-44 ml/kg de peso corporal | 0.025-0.044 L/kg de peso corporal |
| Globulos rojos, mujeres | red blood cells | Blood | 20-30 ml/kg de peso corporal | 0.02-0.03 L/kg de peso corporal |
| Globulos rojos, varones | Erythrocins, men | Blood | 25-35 ml/kg de peso corporal | 0.025-0.035 L/kg de peso corporal |
| Peptido natriuretico cerebral (de tipo B) | Brain natriuretic peptide | Plasma | <100 pg/mL | — |
| Calcitonina, edad ≥ 16 anos: | Calcitonin, from 16 years old: | |||
| Mujeres | Women | Serum | <8 pg/ml | — |
| Varones | Men | Serum | <16 pg/ml | — |
| Calcio | Calcium | Serum | 9-10.5 mg/dL | 2.2 a 2.6 mmol/L |
| Antigeno del Cancer (CA): | Tumor markers: | |||
| CA 125 | Serum | <35 U/mL | — | |
| CA 15-3 | Serum | <30 U/mL | — | |
| Contenido de dióxido de carbono (CO2) | Amount of carbon dioxide | Serum | 23-28mEq/L | 23-28 mmol/L |
| Presión parcial de dióxido de carbono (PCO2) | Partial pressure of carbon dioxide | Blood | 35-45mm Hg | — |
| Carboxihemoglobina | Carboxyhemoglobin | Plasma | 0.5–5% | — |
| Antigeno carcinoembrionario (CEA) | Carcinoembryonic antigen (CEA) | Serum | < 2 ng/mL | < 2 µg/L |
| caroteno | carotene | Serum | 75–300 µg/L | 1.4-5.6 µmol/L |
| Relacion CD4:CD8 | CD4:CD8 ratio | Blood | 1–4 | — |
| Recuento de linfocitos T CD4+ | CD4+ T lymphocyte count | Blood | 640-1175/μL | 0.64 a 1.18 x 109/L |
| Recuento de linfocitos T CD8+ | CD8+ T lymphocyte count | Blood | 335-875/μL | 0.34 - 0.88 x 109/L |
| Ceruloplasmina | ceruloplasmin | Serum | 25-43 mg/dL | 250-430 mg/L |
| Cloro | Chror | Serum | 98-106mEq/L | 98-106 mmol/L |
| Colesterol, nivel deseable: | Cholesterol: | |||
| Lipoproteina de alta densidad (HDL-C) | high density lipoprotein | Plasma | ≥ 40 mg/dL | ≥ 1.04 mmol/L |
| Lipoproteina de baja densidad (LDL-C) | low density lipoprotein | Plasma | ≤ 130 mg/dL | ≤ 3.36 mmol/L |
| Total (TC) | total cholesterol | Plasma | 150-199 mg/dl | 3.88 a 5.15 mmol/L |
| Factors de coagulation: | Blood clotting factors: | |||
| Factor I | Factor I | Plasma | 150–300 mg/dL | 1.5-3.5g/L |
| Factor II | Factor II | Plasma | 60-150% de lo normal | — |
| Factor IX | Factor IX | Plasma | 60-150% de lo normal | — |
| Factor V | Factor V | Plasma | 60-150% de lo normal | — |
| Factor VII | Factor VII | Plasma | 60-150% de lo normal | — |
| Factor VIII | Factor VIII | Plasma | 60-150% de lo normal | — |
| Factor X | Factor X | Plasma | 60-150% de lo normal | — |
| Factor XI | Factor XI | Plasma | 60-150% de lo normal | — |
| Factor XII | Factor XII | Plasma | 60-150% de lo normal | — |
| Complemento: | Complement system: | |||
| C3 | Serum | 55-120 mg/dL | 0.55 a 1.20 g/L | |
| C4 | Serum | 20–59 mg/dL | 0.20 a 0.59 g/L | |
| Total | Total | Serum | 37-55 U/mL | 37-55 kU/L |
| Cobre | Copper | Serum | 70-155µg/L | 11 - 24.3 µmol/L |
| Cortisol: | Cortisol: | |||
| 1 h despues de cosintropina | 1 hour after cosyntropin (cortrosin) | Serum | > 18 µg/dL and allowable ≥ 8 µg/dL from base value | > 498 nmol/L and allowable ≥ 221 nmol/L from baseline |
| A Las 5 p.m. | At 5 am | Serum | 3-13µg/dL | 83 - 359 nmol/L |
| A Las 8 a.m. | At 8 o'clock in the evening | Serum | 8-20µg/dL | 251-552 nmol/L |
| Luego de prueba de supresion nocturna | Nocturnal suppression test | Serum | <5 μg/dL | <138 nmol/L |
| C-peptido | C-peptide | Serum | 0.9 - 4.3 ng/mL | 297-1419 pmol/L |
| Proteina C reactive (CRP) | Inflammatory reactive protein C | Serum | < 0.5 mg/dL | <0.005 g/L |
| Proteina C reactive, altamente sensible (hsCRP) | Ultrasensitive inflammatory protein | Serum | <1,1 mg/L | <0,0011 g/L |
| Creatina cinasa (CK) | Creatine kinase | Serum | 30-170U/L | 0.5 a 2.83 μkat/L |
| Creatinina | Creatinine | Serum | 0.7-1.3 mg/dL | 61.9-115 µmol/L |
| Dimero-d | D-dimer | Plasma | ≤ 300 ng/mL | ≤ 300 µg/L |
| Dehidroepiandrosterona sulfato (DHEA-S): | Dehydroepiandrosterone sulfate: | |||
| Mujeres | Women | Plasma | 0.6 to 3.3 mg/mL | 1.6-8.9 µmol/L |
| Varones | Men | Plasma | 1.3 a 5.5 mg/mL | 3.5-14.9 µmol/L |
| Ácido δ-aminolevulinico (ALA) | Delta-aminolevulinic acid | Serum | 15-23 µg/L | 1.14–1.75 µmol/L |
| 11-desoxicortisol (DOC): | 11-deoxycortisol | |||
| Luego de metirapona | after taking metyrapone | Plasma | > 7 µg/dL | > 203 nmol/L |
| Basal | base value | Plasma | <5 μg/dL | <145 nmol/L |
| Nivel de d-Xylose 2 h después de la ingestion de 25 g de d-xylose | D-xylose level 2 hours after ingestion of 25 g of D-xylose | Serum | > 20 mg/dL | > 1.3 nmol/L |
| Epinefrina, en decubito supino | epinephrine, lying down | Plasma | < 75 ng/L | < 410 pmol/L |
| Velocidad de eritrosedimentación (ESR): | Erythrocyte sedimentation rate: | |||
| Mujeres | Women | Blood | 0-20mm/h | 0-20mm/h |
| Varones | Men | Blood | 0-15mm/h | 0-20mm/h |
| erythropoietina | Erythropoietin | Serum | 4 a 18.5 mUI/mL | 4 - 18.5 UI/L |
| Estradiol, mujeres: | Estradiol, women: | |||
| Dia 1-10 del ciclo menstrual | Day 1-10 from the start of the menstrual cycle | Serum | 14-27pg/ml | 50-100 pmol/L |
| Día 11 - 20 del ciclo menstrual | Day 11-20 from the start of the menstrual cycle | Serum | 14-54 pg/mL | 50-200 pmol/L |
| Día 21 a 30 del ciclo menstrual | Day 21-30 from the start of the menstrual cycle | Serum | 19-40pg/ml | 70-150 pmol/L |
| Estradiol, varones | Estradiol, men | Serum | 10-30pg/mL | 37-110 pmol/L |
| Ferritina | ferritin | Serum | 15–200 ng/mL | 15-200µg/L |
| α‑Fetoproteina (AFP) | Alpha fetoprotein | Serum | 0-20ng/dL | 0-20pg/L |
| Fibrinogeno | fibrinogen | Plasma | 150-350 mg/dL | 1.5 a 3.5 g/L |
| Folato (ácido fólico): | Folic acid: | Serum | 2.7-17.5 ng/mL | 6.00 a 38.50 nmol/L |
| Erytrocitos | red blood cells | Blood | 160-855 ng/mL | 362-1937 nmol/L |
| Suero | Serum | Serum | 2.5–20 ng/mL | 5.7 a 45.3 nmol/L |
| Hormona folículoestimulante (FSH), mujeres | Follicle stimulating hormone, women: | |||
| Face folicular or face lútea | Hormone in the follicular phase of the cycle | Serum | 5-20 mU/mL | 5-20U/L |
| Pico de la mitad del ciclo | The peak of the hormone in the middle of the cycle | Serum | 30-50 mU/mL | 30-50U/L |
| Posmenopausicas | Hormone during the postmenopausal phase | Serum | > 35 mU/mL | > 35U/L |
| Hormona folículoestimulante (FSH), varones adultos | Follicle stimulating hormone, adult men | Serum | 5-15 mU/mL | 5-15U/L |
| Fructosamina | Fructosamine | Plasma | 200-285mol/L | — |
| Gamma‑glutamil transpeptidasa (GGT) | Gamma-glutamyl transpeptidase (GGPT)/transferase | Serum | 8-78 U/L | — |
| Gastrina | Gastrin | Serum | 0-180 pg/mL | 0-180ng/L |
| Globulinas: | Globulins | Serum | 2.5 a 3.5 g/dL | 25-35g/L |
| α1-Globulinas | alpha 1 globulin | Serum | 0.2 - 0.4gdL | 2 - 4 g/L |
| α2-Globulinas | alpha 2 globulin | Serum | 0.5-0.9 g/dL | 5-9g/L |
| Beta-globulinas | beta globulin | Serum | 0.6 - 1.1 g/dL | 6–11 g/L |
| Gamma-globulinas | gamma globulin | Serum | 0.7 - 1.7 g/dL | 7 - 17g/L |
| β2-Microglobulina | beta-2 microglobulin | Serum | 0.7 - 1.8 µg/mL | — |
| Glucose: | Glucose: | |||
| 2nd postprandial | two hours after taking | Plasma | < 140 mg/dL | < 7.8 mmol/L |
| Ayuno | on an empty stomach | Plasma | 70-105 mg/dL | 3.9 - 5.8 mmol/L |
| Glucosa-6-fosfato deshidrogenasa (G6PD) | Glucose-6-phosphate dehydrogenase | Blood | 5-15 U/g Hb | 0.32 a 0.97 mU/mol Hb |
| Gamma‑Glutamil transpeptidasa (GGT) | Gamma-Glutamyl transpeptidase (GGT)/transferase | Serum | 8-78 U/L | — |
| Hormona de crecimiento: | A growth hormone: | |||
| Despues de la glucosa oral | After taking glucose | Plasma | < 2 ng/mL | < 2 µg/L |
| En respuesta a estimulo provocador | Response to a stimulus | Plasma | > 7 ng/mL | > 7 µg/L |
| Haptoglobina | Haptoglobin | Serum | 30-200 mg/dL | 300-2000 mg/L |
| Hematocrito: | Hematocrit: | |||
| Mujeres | Women | Blood | 36–47% | — |
| Varones | Men | Blood | 41–51% | — |
| Hemoglobin: | Hemoglobin: | |||
| Mujeres | Women | Blood | 12-16g/dl | 120-160g/L |
| Varones | Men | Blood | 14-17 g/dl | 140-170g/L |
| Hemoglobina A1c | Hemoglobin A1C / Glycated hemoglobin | Blood | 4.7–8.5% | — |
| Electroforesis de hemoglobina, adultos: | Hemoglobin electrophoresis, adults: | |||
| Hb A1 | Hemoglobin A1 | Blood | 95–98% | — |
| Hb A2 | Hemoglobin A2 | Blood | 2–3% | — |
| Hb C | Hemoglobin C | Blood | 0 | — |
| Hb F | Hemoglobin F | Blood | 0.8–2.0% | — |
| HbS | Hemoglobin S | Blood | 0 | — |
| Electroforesis de hemoglobina, Hb F en niños: | Hemoglobin electrophoresis, fetal hemoglobin F in children: | |||
| neonato | Newborn | Blood | 50–80% | — |
| 1-6 months | 1-6 months | Blood | 0.08 | — |
| > 6 months | from six months | Blood | 1–2% | — |
| Homocysteine: | Homocysteine: | |||
| Mujeres | Women | Plasma | 0.40 a 1.89 mg/L | 3-14 µmol/L |
| Varones | Men | Plasma | 0.54 a 2.16 mg/L | 4–16 µmol/L |
| Gonadotropina coriónica humana (hCG), cuantitativa. | Human chorionic gonadotropin, quantity | Serum | < 5 mUI/mL | — |
| Inmunoglobulins: | Immunoglobulins: | |||
| IgA | IgA | Serum | 70-300 mg/dL | 0.7 a 3 g/L |
| IgD | IgD | Serum | < 8 mg/dL | <80 mg/L |
| IgE | IgE | Serum | 0.01 - 0.04 mg/dL | 0.1-0.4 mg/L |
| IgG | IgG | Serum | 640–1430 mg/dL | 6.4 a 14.3 g/L |
| IgG1 | IgG1 | Serum | 280-1020 mg/dL | 2.8 - 10.2 g/L |
| IgG2 | IgG2 | Serum | 6'–790 mg/dL | 0.6 - 7.9 g/L |
| IgG3 | IgG3 | Serum | 14-240 mg/dL | 0.14 - 2.4 g/L |
| IgG4 | IgG4 | Serum | 11 - 330 mg/dL | 0.11 - 3.3 g/L |
| IgM | IgM | Serum | 20–45 mg/dL | 0.2 - 1.4 g/L |
| Insulina, en ayunas | insulin, fasting | Serum | 1.4-14µIU/mL | 10-104 pmol/L |
| Relación normalizada internacional (international normalized ratio, INR) | Prothrombin test / MHO/INR: | |||
| Rango terapéutico (terapia de intensidad estandar) | Standard Therapeutic Value | Plasma | 2.0–3.0 | — |
| Rango terapéutico en pacientes con mayor riesgo (p. ej., pacientes con válvulas cardíacas protésicas) | Desired INR in Patients at Cardiovascular Risk | Plasma | 2.5–3.5 | — |
| Rango terapéutico en pacientes con lupus anticoagulante | INR value in patients with lupus erythematosus | Plasma | 3.0–3.5 | — |
| Hierro | Iron | Serum | 60-160µg/dL | 11–29 µmol/L |
| Capacidad total de fijación del hierro (TIBC) | Iron-binding capacity, total (TIBC) | Serum | 250-460µg/dL | 45-82 µmol/L |
| lactato dehidrogenasa (LDH) | lactate dehydrogenase | Serum | 60-160U/L | 1-1.67µkat/L |
| Acido láctico, venoso | Lactic acid, in venous blood | Blood | 6-16 mg/dL | 0.67 a 1.8 mmol/L |
| Prueba de tolerancia a la lactosa | Lactose Tolerance Test | Plasma | > 15 mg/dL de aumento en el nivel de glucosa en plasma | > 0.83 mmol/L de aumento en el nivel de glucosa en plasma |
| Plomo | Lead | Blood | less< 40 µg/dL | <1,9 μmol/L |
| Fosfatasa alcalina leucocitica (LAP) | Alkaline phosphatase leukocyte / leukocyte | blood smear | 13-130/100/polimorfonucleares (PMN) leucocitos neutrofilos y bandas | — |
| Lipasa | Lipase | Serum | < 95U/L | < 1.58µkat/L |
| Lipoproteina (a) [Lp (a)] | Lipoprotein | Serum | ≤ 30 mg/dL | < 1.1 µmol/L |
| Hormona luteinizante (LH), mujeres: | Luteinizing hormone, luteotropin, women: | |||
| Fase folicular o lutea | follicular phase | Serum | 5-22 mU/mL | 5-22U/L |
| Pico de la mitad del ciclo | mid-cycle peak | Serum | 30-250 mU/mL | 30-250U/L |
| Posmenopausicas | Postmenopause | Serum | > 30 mU/mL | > 30U/L |
| Hormona luteinizante, varones | luteinizing hormone, luteotropin, men | Serum | 3-15 mU/mL | 3-15U/L |
| Magnesio | Magnesium | Serum | 1.5 to 2.4 mg/dL | 0.62-0.99 mmol/L |
| Manganeso | Manganese | Serum | 0.3-0.9 ng/mL | 5.5 - 16.4 nmol/L |
| Hemoglobina corpuscular media (MCH) | Mean corpuscular hemoglobin (MCH) | Blood | 28-32pg | — |
| Concentración de hemoglobina corpuscular media (MCHC) | Average hemoglobin concentration (MCHC) | Blood | 32-36g/dL | 320-360g/L |
| Volumen corpuscular media (MCV) | Mean red cell volume (MCV) | Blood | 80-100 fL | — |
| Metanephrinas, fraccionado: | Metanephrines, fractions | |||
| Metanephrinas, libre | Metanephrines, free | Plasma | <0,50 nmol/L | — |
| Netanefrinas, libre | Normetanephrines, free | Plasma | < 0.90 nmol/L | — |
| Metahemoglobin | Methemagglobin | Blood | < 1.0% | — |
| Ácido metilmalónico. | Methylmalonic acid | Serum | 150-370nmol/L | — |
| Anticuerpos anti-mieloperoxidasa (MPO) | Antibodies to myeloperoxidase (anti-MPO) | Serum | < 6.0 U/mL | — |
| Myoglobina: | Myoglobin: | |||
| Mujeres | Women | Serum | 25-58 µg/L | 1.4 a 3.5 nmol/L |
| Varones | Men | Plasma | 28–72 µg/L | 1.6 a 4.1 nmol/L |
| Noradrenalina, decubito supino | Norepinephrine, lying down | Plasma | 50-440pg/ml | 0.3 - 2.6 nmol/L |
| Propeptido N-terminal BNP (NT-proBNP) | Brain natriuretic hormone (NT-proBNP) | Plasma | < 125 pg/mL | — |
| 5'-Nucleotidasa (5'NT) | 5'-Nucleosidase | Serum | 4-11.5U/L | — |
| Osmolalidad | Osmolarity | Plasma | 275-295 mOsm/kg H2O | 275-295 mmol/kg H2O |
| Prueba de fragilidad osmotica | Osmotic stability test | Blood | Aumento de la fragilidad si hay hemolisis en NaCl a > 0.5% | — |
| Presion parcial de oxygeno (PO2) | Partial oxygen pressure | Blood | 80-100mm Hg | — |
| Hormona parathyroidea (PTH) | Parathyroid hormone | Blood | 10-65pg/ml | 10-65ng/L |
| Péptido relacionado con la hormona paratiroidea (PTHrP) | Parathyroid hormone-related peptide | Plasma | < 2 pmol/L | — |
| Tiempo parcial de thromboplastina activada (aPTT) | Activated thromboplastin time (aPTT) | Plasma | 25-35 seg | — |
| pH | pH | Blood | 7.38–7.44 | — |
| Fosforo inorganico | Phosphorus, inorganic | Blood | 3.0-4.5 mg/dL | 0.97 - 1.45 mmol/L |
| Recuento de plaquetas | Platelet count | Blood | 150-350 x 103/μL | 150-350x109/L |
| Tiempo de vida de las plaquetas, utilizando cromo-51 (51Cr) | Platelet lifetime using chromium Cr51 | — | 8-12 dias | — |
| Porfirinas | Porphyrins | Plasma | ≤ 1.0µg/dL | — |
| Potasio | Potassium | Serum | 3.5–5 mEq/L | 3.5-5 mmol/L |
| Prealbúmina (transtiretina) | prealbumin | Serum | 18–45 mg/dL | — |
| Progesterone: | Progesterone: | |||
| Phase follicular | follicular phase | Serum | < 1 ng/mL | < 0.03 nmol/L |
| Phase lutea: | luteal phase | Serum | 3–30 ng/mL | 0.1 - 0.95 nmol/L |
| Prolactina: | Prolactin: | |||
| Mujeres | Women | Serum | < 20 µg/L | < 870 pmol/L |
| Varones | Men | Serum | < 15 µg/L | < 652 pmol/L |
| Antigeno prostatico específico, total (PSA-T) | prostate specific antigen | Serum | 0-4 ng/mL | — |
| Próstata-antígeno específico, relación libre/total (PSA-F: PSA-T) | Ratio of specific prostate antigen to free prostate antigen | Serum | > 0,25 | — |
| Actividad de la proteina C | Protein C | Plasma | 67–131% | — |
| Resistencia a proteina C activada (APC-R) | Stability of activated protein C | Plasma | 2.2–2.6 | — |
| Actividad de proteina S | S protein activity | Plasma | 82–144% | — |
| Proteina, total | total protein | Serum | 6-7.8 g/dL | 60-78g/L |
| Tiempo de protrombina (PT) | Prothrombin time | Plasma | 11–13 seg | — |
| Piruvato | pyrubate | Blood | 0.08 - 0.16 mmol/L | — |
| Recuento de globulo rojos | RBC count | Sangre | 4.2 a 5.9 x 106 cells/μL | 4.2 a 5.9 x 1012 cells/L |
| Tasa de supervivencia de los glóbulos rojos, utilizando 51Cr | The survival index of erythrocytes with chromium Cr 51 | Sangre | T1/2 = 28 days | — |
| Actividad de la renina, plasma (PRA), en posición vertical, en varones y mujeres de 18 a 39 años: | Parameters of renal renin in plasma, women and men from 18 to 39 years: | |||
| Depletion de sodio | With the addition of sodium | Plasma | 2.9 - 24ng/mL/h | — |
| Replecion de sodio | By adding sodium | Plasma | 0.6 (o inferior) -4.3 ng/mL/h | — |
| Recuento de reticulocitos | Reticulocytes: | |||
| Porcentaje | Percentage in blood | Blood | 0.5–1.5% | — |
| Absolutely | Absolute value | Blood | 23-90 x 103/μL | 23-90x109/L |
| Factor reumatoide (RF) | Rheumatoid factor | Serum | < 40 U/mL | < 40 kU/L |
| sodio | Sodium | Serum | 136-145mEq/L | 136-145 mmol/L |
| Testosterone, adults: | Testosterone, adults: | |||
| Mujeres | Women | Serum | 20–75 mg/dL | 0.7 - 2.6 nmol/L |
| Varones | Men | Serum | 300–1200ng/dL | 10-42nmol/L |
| Tiempo de trombina | Prothrombin time | Plasma | 18.5-24 seg | — |
| Captación tiroidea de yodo-123 (123I) | Thyroid capture of iodine-123 | — | 5-30% de la dosis administrada a las 24 h | — |
| Tirotropina (TSH) | Thyrotropic hormone | Serum | 0.5–5.0 µUI/mL | 0.5-5.0mUI/L |
| Thyroxina (T4): | thyroxine | |||
| Libre | Free | Serum | 0.9-2.4ng/dL | 12-31 pmol/L |
| Candice libre | Free | — | 4-11 g/dL | — |
| Total | General (+protein-bound) | Serum | 5-12µg/dL | 64 - 155 nmol/L |
| Transferrina | transferrin | Serum | 212-360 mg/dL | 2.1 a 3.6 g/L |
| Saturacion de transferrina | Transferrin saturation | Serum | 20–50% | — |
| Triglyceridos (nivel deseable) | Triglycerides | Serum | < 250 mg/dL | < 2.82 mmol/L |
| Triyodotironina (T3): | Triiodothyronine T3 | |||
| Captacion | Capture T3 | Serum | 25–35% | — |
| Total | General | Serum | 70 - 195 ng/dL | 1.1 a 3.0 nmol/L |
| Troponina I | Troponin I | Plasma | < 0.1 ng/mL | < 0.1 µg/L |
| Troponina T | Troponin T | Serum | ≤ 0.03 ng/mL | ≤ 0.03µg/L |
| Nitrogeno ureico (BUN) | blood urea nitrogen | Serum | 2.9 a 7.1 mmol/L | |
| Ácido úrico | Uric acid | Serum | 2.5-8 mg/dL | 0.15-0.47 mmol/L |
| Vitamin B12 | Vitamin B12 | Serum | 200–800 pg/mL | 148-590 pmol/L |
| Vitamina C (acido ascorbico) | Vitamin C | |||
| Leucocitos | Leukocytes | Blood | < 20 mg/dL | <1,136 μmol/L |
| Total | The total number of leukocytes | Blood | 0.4-1.5 mg/dL | 23–85 µmol/L |
| Vitamin D: | VITAMIN D | |||
| 1,25-dihidroxicolecalciferol (calcitriol) | Calcitriol | Blood | 25–65 pg/mL | 65-169 pmol/L |
| 25-hydroxicolecalciferol | Dihydrocholecalciferol | Blood | 15–80 ng/mL | 37 - 200 nmol/L |
| Recuento de leucocitos | WBC count | Blood | 3.9 - 10.07 x 103 cells/μL | 3.9 - 10.7 x 109 cells/L |
| Cinc | Zinc | Serum | 66-110µg/dL | 10.1 - 16.8 µmol/dL |
Advantages of VALINTERMED
Specialists Valintermed help you get a blood test in Spain quickly and anonymously.
We offer a quick and anonymous analysis for genitourinary infections (STD test) in Valencia. Results are usually obtained within two to three days. A culture and an antibiogram are performed, which gives you the opportunity to immediately prescribe treatment.
You can get a referral for tests from anywhere in Spain under your insurance policy within an hour. All you need is to send a request for this service. If you need medical advice, it can be provided in Russian.
